ImmunityBio, Inc. 8-K

What Happened
ImmunityBio, Inc. (IBRX) filed a Form 8-K on May 18, 2026 reporting that on May 14, 2026 it entered an exclusive development and supply agreement with Japan BCG Laboratory (JBL) for the Tokyo‑172 strain of Bacillus Calmette‑Guérin (BCG). The Company issued a press release on May 16, 2026 announcing the agreement. Under the deal, JBL will manufacture and exclusively supply the Product for the United States and its territories, while ImmunityBio will handle all development, clinical trials, and regulatory approvals required for U.S. commercialization.

Key Details

• Agreement date: May 14, 2026; Form 8-K filed May 18, 2026; press release issued May 16, 2026.
• Product: Tokyo‑172 strain of BCG; Territory: United States and its territories.
• Exclusivity: ImmunityBio has exclusive rights to purchase, import, sell and distribute the Product in the Territory for an initial term of 10 years measured from the date of FDA approval.
• Payments and obligations: No payments due to JBL prior to FDA approval; vials for regulatory submissions provided at no cost; post-approval ImmunityBio committed to purchase at least two batches per year and will use commercially reasonable efforts to launch and commercialize.
• Other terms: ImmunityBio has a right of first negotiation for development/commercialization rights outside the Territory (with certain Asian regions excluded, including Japan); standard representations, warranties, indemnities, confidentiality, and termination rights (including for material breach or insolvency and a company convenience termination).

Why It Matters
This agreement secures a manufacturing and supply relationship for a specific BCG strain (Tokyo‑172) important to ImmunityBio’s development plans in the U.S., while placing responsibility for clinical development and FDA approval squarely on ImmunityBio. For investors, the deal reduces near‑term manufacturing risk (a named supplier is in place) and defers cash outflows to post‑approval, but commercialization and regulatory risk remain with the company until FDA approval is achieved.